- Home
- CABR vs QNRX Comparison
CABR vs QNRX Comparison
Compare CABR & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CABR | QNRX |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 14.5M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | CABR | QNRX |
|---|---|---|
| Price | $0.99 | $6.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 48.8K | 24.0K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $5.20 |
| 52 Week High | $1.65 | $41.80 |
Technical Indicators
Market Signals| Indicator | CABR | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 49.35 |
| Support Level | $0.78 | $5.34 |
| Resistance Level | $1.08 | $6.98 |
| Average True Range (ATR) | 0.12 | 0.44 |
| MACD | -0.03 | 0.14 |
| Stochastic Oscillator | 14.92 | 78.02 |
Price Performance
Historical ComparisonAbout CABR Caring Brands Inc.
Caring Brands Inc is a wellness consumer products company. It offers several over-the-counter (OTC) and cosmetic consumer products. Its product pipeline includes a diverse products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products, catering to diverse health and wellness needs. It operates in a single segment.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.